The prognostic value of the pretreatment serum CA 125, squamous cell carcinoma antigen (SCC), and carcinoembryonic antigen (CEA) levels in relation to tumor type, vascular invasion by tumor cells, and lymph node metastases was investigated in 77 patients with cervical adenocarcinoma. In Stage IB (International Federation of Gynecology and Obstetrics [FIGO]), the five-year actuarial survival of patients with pretreatment serum CA 125 levels greater than 16 U/ml was 52.4% versus 95.6% when normal serum CA 125 levels were determined (P less than 0.01). Pretreatment serum SCC or CEA levels had no substantial prognostic value. In Stage IB (FIGO), 42% of the patients with elevated serum CA 125 levels had lymph node metastases versus 4% when normal levels were found (P = 0.012). The presence of vascular invasion (P = 0.01) or lymph node metastases (P = 0.001) was associated with an increased risk for recurrent disease. Adenosquamous tumors showed a higher incidence of vascular invasion (P = 0.05) and a higher incidence of elevated serum CA 125 levels (P = 0.03). Particularly in Stage II, adenosquamous tumors were found to have a poorer prognosis than adenocarcinomas (P = 0.0566). We conclude that in cervical adenocarcinoma serum CA 125 is an important prognostic factor and an implicit indicator of tumor virulence.

译文

研究了77例宫颈腺癌患者的治疗前血清CA 125,鳞状细胞癌抗原 (SCC) 和癌胚抗原 (CEA) 水平与肿瘤类型,肿瘤细胞的血管浸润和淋巴结转移的关系的预后价值。在IB期 (国际妇产科联合会 [FIGO]) 中,在测定正常血清CA 125水平时,治疗前血清CA 125水平大于16 u/ml的患者的五年精算生存期为52.4%,而95.6% 为 (P小于0.01)。治疗前血清SCC或CEA水平没有实质性的预后价值。在IB期 (FIGO) 中,42% 血清CA 125水平升高的患者有淋巴结转移,而发现正常水平时则有4% (P = 0.012)。血管侵犯 (P = 0.01) 或淋巴结转移 (P = 0.001) 与复发风险增加相关。腺鳞癌的血管侵犯发生率较高 (P = 0.05),血清CA 125水平升高的发生率较高 (P = 0.03)。特别是在II期,发现腺鳞癌的预后比腺癌差 (P = 0.0566)。我们得出结论,在宫颈腺癌中,血清CA 125是重要的预后因素,也是肿瘤毒力的隐性指标。

+1
+2
100研值 100研值 ¥99课程
检索文献一次
下载文献一次

去下载>

成功解锁2个技能,为你点赞

《SCI写作十大必备语法》
解决你的SCI语法难题!

技能熟练度+1

视频课《玩转文献检索》
让你成为检索达人!

恭喜完成新手挑战

手机微信扫一扫,添加好友领取

免费领《Endnote文献管理工具+教程》

微信扫码, 免费领取

手机登录

获取验证码
登录